Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed)
ID: 351471Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $5M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351471

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-065.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Centers of Excellence for Translational Research (CETR) program, aimed at advancing multidisciplinary research on medical countermeasures against drug-resistant bacteria and fungi. This initiative seeks to support collaborative centers that will focus on transforming basic scientific knowledge into innovative prevention, diagnosis, and treatment strategies for emerging antimicrobial resistance (AMR), with an emphasis on therapeutics, vaccines, and diagnostics. A total funding amount of $25 million is available for 3-4 grants, with individual project budgets capped at $5 million over a maximum five-year period. The application period opens on March 29, 2024, and closes on April 30, 2024; interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-23-065-Full-Announcement.html
    RFA-AI-23-065.html
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), seeks applications for funding under the Centers of Excellence for Translational Research (CETR) program. This initiative aims to advance multidisciplinary translational research on medical countermeasures against drug-resistant bacteria and fungi. The program emphasizes research activities that transform basic scientific knowledge into novel prevention, diagnosis, and treatment approaches for emerging antimicrobial resistance (AMR). Funding will support collaborative centers focusing on various research themes such as therapeutics, vaccines, and diagnostics targeting specific AMR pathogens. A total of $25 million is planned for 3-4 grants, with project budgets capped at $5 million over a maximum five-year period. Applications must involve a comprehensive Product Development Strategy and address regulatory challenges. The call encourages participation from diverse institutions, including historically underrepresented organizations, highlighting the importance of innovative and diverse research teams to combat public health threats posed by antibiotic resistance. The application period opens on March 29, 2024, with an expiration date set for April 30, 2024.
    Similar Opportunities
    Centers of Excellence in Healthcare Quality: Detecting and Responding to Threats to Healthcare Safety
    Centers for Disease Control - NCEZID
    The Centers for Disease Control - NCEZID is offering a federal grant opportunity titled "Centers of Excellence in Healthcare Quality: Detecting and Responding to Threats to Healthcare Safety." This initiative aims to establish a collaborative network among healthcare systems, facilities, and public health partners to enhance the detection, response, and prevention of threats to patient and healthcare worker safety, ultimately improving the quality and resilience of U.S. healthcare delivery. The program is particularly relevant for various healthcare settings, including hospitals, nursing homes, and outpatient facilities, and encourages partnerships with public health departments and relevant entities. Interested applicants can apply for funding ranging from $2.5 million to $15 million, with an estimated total program funding of $750 million and an expected ten awards. Applications must be submitted electronically by June 5, 2026, with the anticipated award date set for August 1, 2026. For further inquiries, applicants may contact Carla Doan at gon5@cdc.gov or by phone at 770-488-8354.
    Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases
    Centers for Disease Control - NCEZID
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement titled "Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases." This initiative aims to enhance the nation's capacity to prevent, detect, and respond to infectious disease threats by supporting healthcare professionals, systems, and organizations involved in public health and patient care. The program emphasizes strengthening critical infrastructure, workforce training, and emergency response capabilities, particularly focusing on antimicrobial resistance and infection control. With an estimated total funding of $150 million, the CDC anticipates awarding approximately 15 grants, with individual awards ranging from $1 million to $30 million. Interested applicants can contact Trisia Shannon at 404-639-0063 or via email at xki5@cdc.gov, with applications due by April 18, 2026, and project start dates expected by September 30, 2026.
    Centers of Excellence in Genomic Science (CEGS)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Centers of Excellence in Genomic Science (CEGS) program, aimed at fostering interdisciplinary research teams to tackle significant biomedical challenges from a genomics perspective. The initiative seeks to develop innovative concepts, methods, and technologies that can lead to transformative advancements in genomic science, genomic medicine, and computational genomics, with a focus on high-risk, high-reward projects that are unlikely to be pursued through standard funding mechanisms. With an estimated total program funding of $5 million and the expectation of awarding two grants, interested applicants can reach out to Stephanie A. Morris at morriss2@mail.nih.gov or call 301-435-5738 for further information. The application process is set to open with a synopsis posting on March 25, 2026, and will close on June 24, 2026, with awards anticipated by April 1, 2027.
    Centers for AIDS Research (CFAR)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Centers for AIDS Research (CFAR)" aimed at advancing HIV/AIDS research through the establishment and support of a national network of CFARs. This initiative seeks to foster multidisciplinary collaborations and provide infrastructure that enhances the efficiency and effectiveness of HIV/AIDS research, particularly by supporting early-career investigators and funding innovative pilot studies. With an estimated total program funding of $4,202,000 and an expected six awards, interested applicants, including various organizations and non-domestic entities, should note that the application period is open until August 19, 2026, with awards anticipated to be made by March 1, 2027. For further inquiries, applicants can contact the CFAR Program at CFARprogram@mail.nih.gov or call 240-459-2852.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Coccidioidomycosis Collaborative Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Coccidioidomycosis Collaborative Research Centers" aimed at advancing research to develop a vaccine for coccidioidomycosis, commonly known as Valley fever. This initiative seeks to support multi-disciplinary research centers that will address critical gaps in basic research, develop necessary tools and resources, and ultimately create a preventative vaccine for this serious fungal infection endemic to various regions in the United States. The grant is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, community-based organizations, and foreign institutions, with no cost-sharing or matching requirement. Interested parties can reach out to Dr. Dona Love at dona.love@nih.gov or by phone at 301-761-7788 for further information. The estimated synopsis post date is January 5, 2026, with a closing date for applications on March 6, 2026, and an anticipated award date of December 1, 2026.
    Infectious Diseases Clinical Trials Network (IDCTN)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Infectious Diseases Clinical Trials Network (IDCTN)" aimed at advancing public health through the rapid implementation of clinical trials for infectious diseases. This initiative seeks to establish a network comprising Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC) to evaluate therapeutics, vaccines, diagnostics, and devices, addressing urgent public health needs that standard grant timelines cannot meet. With an estimated total program funding of $29 million, this opportunity is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, and community-based organizations. Interested parties can reach out to Dr. Marina S. Lee at 240-627-3304 or via email at dmidclinicaltrials@niaid.nih.gov for further information, with key deadlines including an estimated synopsis close date of June 11, 2026, and an anticipated award date of March 1, 2027.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Chemical Countermeasures Research Program (CCRP) Initiative, aimed at supporting research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, such as fentanyl and carfentanil. This initiative seeks to advance understanding of both immediate and delayed health impacts associated with these substances, emphasizing innovative research into toxicity mechanisms and the development of new therapeutic strategies. The program will provide up to four grants, with a maximum award of $300,000 annually over a potential five-year period, totaling an estimated $2 million in funding. Interested applicants, including various educational and nonprofit institutions, must submit their proposals by November 18, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)
    Agency for Health Care Research and Quality
    The Agency for Healthcare Research and Quality (AHRQ) is offering a funding opportunity for Large Research Projects aimed at combating Antibiotic-Resistant Bacteria (CARB). This initiative invites applications for grant funding to enhance appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent healthcare-associated infections across various healthcare settings. With a focus on addressing significant public health threats posed by antibiotic resistance, the grants can fund projects up to $2.5 million over five years, with annual budgets not exceeding $500,000. Interested applicants must adhere to detailed submission guidelines, and the application deadline is October 30, 2026. For further inquiries, applicants can contact AHRQ at GrantQueries@ahrq.hhs.gov.
    Opportunities for Collaborative Research at the NIH Clinical Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center," aimed at supporting collaborative translational research projects that enhance the application of basic biological discoveries to clinical settings. This program encourages partnerships between NIH intramural investigators and extramural researchers to accelerate patient-centric translational research, focusing on understanding disease processes and developing new therapeutic interventions, diagnostics, or prevention strategies. Interested small businesses can apply for this cooperative agreement, with no cost-sharing requirement, and should note that the estimated synopsis post date is September 1, 2025, with a closing date of December 12, 2025. For further inquiries, applicants can contact Dr. David J. Eckstein at 301-496-4121 or via email at ClinicalCtrPartner@mail.nih.gov.